Skip to main content
Caplight Logo









Progenra, Inc.

Progenra, Inc.

Private
Malvern, PennsylvaniaHealthcare & Life Scienceshttps://progenra.com/

Last Round

Grant

May 16, 2025

Total Funding Raised

$7.81M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Progenra, Inc. is a biotechnology company that develops novel therapeutics targeting the ubiquitin-proteasome system, including molecular glues and targeted protein degradation for neurodegenerative, cardiovascular, and metabolic diseases.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts, Data as a Service

AI Layer

Non-AI

Keywords

drug discoveryprotein degradationPROTACsmolecular gluesubiquitin-proteasome systemUPStargeted protein degradationTPDsmall-molecule therapeuticsbiotechnologymitochondrial biologypreclinical drug developmentdrug licensinghigh-throughput screeningHTSmedicinal chemistry

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Progenra, Inc. Comparables

Compare Progenra, Inc. with similar companies based on industry and business-model similarity.

Progenra, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
SEED Therapeutics
85%
GluBio Therapeutics
83%
Dunad Therapeutics
81%

Progenra, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMay 16, 2025
GrantSep 20, 2024
GrantSep 1, 2022
GrantSep 1, 2020
GrantMay 26, 2020

Key People

Founding team and executive leadership

Tauseef Butt

President and CEO

Executive Team

Mike Mattern

Vice President and COO

Executive Team

Progenra, Inc. Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 2, 2026

    Grew 33% QoQ from 9 to 12 employees.

  • Jul 24, 2026

    Monthly visitors increased 36% MoM, reaching 2.4K.

Progenra, Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Progenra, Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Progenra, Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersMalvern, Pennsylvania
Employee Range12
Year Founded2002
Last FundingMay 16, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?